Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patients

10/23/2020 | 05:20pm EST
SPECIALIZED PRESS
Friday - October 23, 2020
Bitte JavaScript aktivieren / Please enable JavaScript



About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

(1) FoundationOne CDx Technical Information. Foundation Medicine, Inc. https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf.
(2) VITRAKVI [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2019.

Find more information at www.pharma.bayer.com
Follow us on Facebook: http://www.facebook.com/pharma.bayer
Follow us on Twitter: @BayerPharma

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Disclaimer

Bayer AG published this content on 23 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 October 2020 21:19:02 UTC


© Publicnow 2020
All news about BAYER AG
11/24BAYER : Film About Pivotal Canadian Patent Case Attracting Controversy
AQ
11/19BAYER : initiates new G4A Digital Health Partnerships Program
AQ
11/18BAYER : Finerenone showed consistent benefits on cardiovascular outcomes in pati..
AQ
11/13BAYER : Metagenomi closes USD 65 million Series A financing led by Leaps by Baye..
AQ
11/12BAYER : Invests in US Gene-Editing Company Metagenomi
DJ
11/12BAYER AG : Goldman Sachs reiterates its Buy rating
MD
11/12BAYER : Metagenomi closes USD 65 million Series A financing led by Leaps by Baye..
PU
11/10BAYER CROPSCIENCE LIMITED : reports Q2 results for FY 2020-21
AQ
11/09BAYER : makes 'substantial progress' in Roundup cancer lawsuits, mediator says
RE
11/09BAYER : Applies for US, EU Marketing Authorization for Finerenone
DJ
More news
Financials
Sales 2020 42 034 M 50 174 M 50 174 M
Net income 2020 -10 295 M -12 288 M -12 288 M
Net Debt 2020 34 614 M 41 317 M 41 317 M
P/E ratio 2020 -4,44x
Yield 2020 4,46%
Capitalization 48 281 M 57 498 M 57 631 M
EV / Sales 2020 1,97x
EV / Sales 2021 1,93x
Nbr of Employees 100 618
Free-Float 100,0%
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 61,28 €
Last Close Price 49,15 €
Spread / Highest target 73,0%
Spread / Average Target 24,7%
Spread / Lowest Target -6,40%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-32.50%57 498
JOHNSON & JOHNSON-1.50%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-1.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273